Security
PODD · INSULET CORP
PODDNASDAQCommon stockCurrentCIK 1145197Updated Sep 27, 2026
PODD price & chart
Loading TradingView…
NASDAQ:PODD on TradingView ↗About the company
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com.
In the news
Important Notice to Long-Term Shareholders of Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); Insulet Corporation (NASDAQ: PODD); and York Space Systems Inc. (NYSE: YSS): Grabar Law Office is Investigating Claims on Your Behalf ↗
Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers - PODD ↗
Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers - PODD ↗
Recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,190,400,000Source | 3,087,700,000Source | 2,588,200,000Source | 2,251,100,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | 599,900,000Source |
| GoodwillUSD | 51,600,000Source | 51,500,000Source | 51,700,000Source | 51,700,000Source |
| Current assets: | ||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 140,900,000Source |
| Inventory, NetUSD | 452,600,000Source | 430,400,000Source | 402,600,000Source | 346,800,000Source |
| Assets, CurrentUSD | 1,914,000,000Source | 1,891,300,000Source | 1,582,900,000Source | 1,314,000,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 228,300,000Source | 142,000,000Source | 116,400,000Source | 86,900,000Source |
| Operating Lease, Right-of-Use AssetUSD | 43,700,000Source | 36,700,000Source | 27,900,000Source | 26,000,000Source |
| Other Assets, NoncurrentUSD | 205,800,000Source | 181,500,000Source | 190,000,000Source | 210,000,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,675,200,000Source | 1,876,100,000Source | 1,855,500,000Source | 1,774,700,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Additional Paid in CapitalUSD | 1,274,900,000Source | 1,184,400,000Source | 1,102,600,000Source | 1,040,600,000Source |
| Retained Earnings (Accumulated Deficit)USD | 287,400,000Source | 40,300,000Source | -378,000,000Source | -584,300,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 12,500,000Source | -13,200,000Source | 8,000,000Source | 20,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,515,200,000Source | 1,211,600,000Source | 732,700,000Source | 476,400,000Source |
| Liabilities and EquityUSD | 3,190,400,000Source | 3,087,700,000Source | 2,588,200,000Source | 2,251,100,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 680,100,000Source | 528,400,000Source | 451,200,000Source | 364,700,000Source |
| Operating Lease, Liability, CurrentUSD | 3,000,000Source | 2,100,000Source | 3,500,000Source | 3,600,000Source |
| Accounts Payable, CurrentUSD | 75,000,000Source | 19,800,000Source | 19,200,000Source | 30,800,000Source |
| Operating Lease, Liability, NoncurrentUSD | 48,900,000Source | 40,000,000Source | 29,500,000Source | 27,400,000Source |
| Other Liabilities, NoncurrentUSD | 64,400,000Source | 51,600,000Source | 37,900,000Source | 35,700,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | — | 301,000,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 18,400,000Source | 83,800,000Source | 49,400,000Source | 27,500,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 1,374,300,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 90,400,000Source | 80,800,000Source | 72,800,000Source | 63,200,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 62,700,000Source | 69,300,000Source | 48,300,000Source | 40,900,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | 99,400,000Source | 12,900,000Source |
| Increase (Decrease) in InventoriesUSD | 10,600,000Source | 32,400,000Source | 53,600,000Source | 49,100,000Source |
| Increase (Decrease) in Accounts PayableUSD | 49,200,000Source | 2,200,000Source | -11,000,000Source | -2,400,000Source |
| Deferred Income Tax Expense (Benefit)USD | 62,300,000Source | -136,900,000Source | 500,000Source | -900,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 569,300,000Source | 430,300,000Source | 145,700,000Source | 119,000,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -222,700,000Source | -146,200,000Source | -119,400,000Source | -191,100,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 3,200,000Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 191,600,000Source | 124,900,000Source | 75,600,000Source | 122,900,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 25,900,000Source | 7,600,000Source | 13,200,000Source | 16,800,000Source |
| Payments for Repurchase of Common StockUSD | 59,600,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -595,300,000Source | -28,100,000Source | -13,600,000Source | -40,300,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 0Source | 0Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -237,300,000Source | 249,200,000Source | 14,500,000Source | -116,700,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 716,100,000Source | 953,400,000Source | 704,200,000Source | 689,700,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 50,800,000Source | 47,100,000Source | 49,900,000Source | 34,200,000Source |
| Income Taxes Paid, NetUSD | 38,500,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 11,500,000Source | -6,800,000Source | 1,800,000Source | -4,300,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 62,600,000Source | 69,300,000Source | 48,300,000Source | 40,900,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 4,300,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 6,200,000Source | 7,300,000Source | 6,700,000Source | 5,800,000Source |
| Amortization of Intangible AssetsUSD | 10,500,000Source | 9,800,000Source | 10,200,000Source | 7,200,000Source |
| Capitalized Computer Software, AmortizationUSD | 32,100,000Source | 26,800,000Source | 20,300,000Source | 12,700,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | -3,800,000Source | — | — |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | 4,700,000Source | — | — | — |
| DepreciationUSD | 79,900,000Source | 71,000,000Source | 62,600,000Source | 56,000,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 2,800,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 1,800,000Source | -2,300,000Source | -400,000Source | -1,300,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -123,900,000Source | — | 0Source | 0Source |
| GoodwillUSD | 51,600,000Source | 51,500,000Source | 51,700,000Source | 51,700,000Source |
| Income Tax Expense (Benefit)USD | 92,400,000Source | -118,100,000Source | 8,300,000Source | 5,200,000Source |
| InterestExpenseNonoperatingUSD | 59,400,000Source | 42,700,000Source | — | — |
| Investment Income, InterestUSD | 34,700,000Source | 39,500,000Source | 28,600,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | 247,100,000Source | 418,300,000Source | 206,300,000Source | 4,600,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 247,100,000Source | 418,300,000Source | 206,300,000Source | — |
| Other Nonoperating Income (Expense)USD | 14,300,000Source | -5,500,000Source | 2,200,000Source | -1,100,000Source |
| Payments to Acquire InvestmentsUSD | 0Source | 12,200,000Source | 7,200,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 19,000,000Source | 8,200,000Source | 16,300,000Source | 6,900,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | 12,500,000Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 0Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 1,055,400,000Source |
| Cost of RevenueUSD | 768,200,000Source | 625,900,000Source | 537,200,000Source | 499,700,000Source |
| Selling, General and Administrative ExpenseUSD | 1,165,000,000Source | 917,200,000Source | 734,900,000Source | 587,800,000Source |
| Operating Income (Loss)USD | 473,800,000Source | 308,900,000Source | 220,000,000Source | 37,600,000Source |
| Other Nonoperating Income (Expense)USD | 14,300,000Source | -5,500,000Source | 2,200,000Source | -1,100,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 339,500,000Source | 300,200,000Source | 214,600,000Source | 9,800,000Source |
| Income Tax Expense (Benefit)USD | 92,400,000Source | -118,100,000Source | 8,300,000Source | 5,200,000Source |
| Net Income (Loss) Attributable to ParentUSD | 247,100,000Source | 418,300,000Source | 206,300,000Source | 4,600,000Source |
| Earnings Per Share, BasicUSD per share | 3.51Source | 5.97Source | 2.96Source | 0.07Source |
| Earnings Per Share, DilutedUSD per share | 3.48Source | 5.78Source | 2.94Source | 0.07Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 70,348,000Source | 70,076,000Source | 69,751,000Source | 69,375,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 71,886,000Source | 73,890,000Source | 73,633,000Source | 69,910,000Source |
| Interest Expense (non-operating)USD | 59,400,000Source | 42,700,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 10,500,000Source | 9,800,000Source | 10,200,000Source | 7,200,000Source |
| Capitalized Computer Software, AmortizationUSD | 32,100,000Source | 26,800,000Source | 20,300,000Source | 12,700,000Source |
| Current Income Tax Expense (Benefit)USD | 30,100,000Source | 18,800,000Source | 7,800,000Source | 6,100,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | -3,800,000Source | — | — |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | 2,800,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 1,800,000Source | -2,300,000Source | -400,000Source | -1,300,000Source |
| Gross ProfitUSD | 1,939,900,000Source | 1,445,700,000Source | 1,159,900,000Source | 805,600,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 248,000,000Source | 253,900,000Source | 199,500,000Source | 11,800,000Source |
| Interest ExpenseUSD | — | — | 36,200,000Source | 36,500,000Source |
| Interest Income (Expense), NetUSD | — | — | — | -26,700,000Source |
| Investment Income, InterestUSD | 34,700,000Source | 39,500,000Source | 28,600,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 247,100,000Source | 418,300,000Source | 206,300,000Source | — |
| Research and Development ExpenseUSD | 301,100,000Source | 219,600,000Source | 205,000,000Source | 180,200,000Source |
Filing attachments
podd2026-06x30ex991.htm · 8-K · 2026-08-05
EX-99.1 2 podd2026-06x30ex991.htm EX-99.1 Document Exhibit 99.1 Insulet Reports Second Quarter 2026 Results Second Quarter Revenue of $802 million, Increase of 23.5% (22.7% in Constant Currency1) ACTON, Mass. - August 5, 2026 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended June 30, 2026. Second Quarter Financial Highli…
Read attachment ↗podd-2026x6x25ex991.htm · 8-K · 2026-06-25
EX-99.1 2 podd-2026x6x25ex991.htm EX-99.1 Document Exhibit 99.1 Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors ACTON, Mass. - June 25, 2026 - (BUSINESS WIRE) - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan (“Jay”) Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Boa…
Read attachment ↗podd-2026x5x26ex991.htm · 8-K · 2026-05-26
EX-99.1 2 podd-2026x5x26ex991.htm EX-99.1 Document Exhibit 99.1 Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets ACTON, Mass., May 26, 2026 -- Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified …
Read attachment ↗podd2026-03x31ex991.htm · 8-K · 2026-05-06
EX-99.1 2 podd2026-03x31ex991.htm EX-99.1 Document Exhibit 99.1 Insulet Reports First Quarter 2026 Results Raises Full Year Total Company Revenue Guidance ACTON, Mass. - May 6, 2026 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: • Revenue of $761.7 million, up 33.9%…
Read attachment ↗podd-2026x3x12ex991.htm · 8-K · 2026-03-12
EX-99.1 2 podd-2026x3x12ex991.htm EX-99.1 Document Exhibit 99.1 Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S. • Medical Device Correction impacts only specific lots of Omnipod® 5 Pods • Customers can visit omnipod.com/check-pods to check lot numbers and request replacement Pods at no cost • All other Omnipod® 5 Pods and Omnipod® products remain safe to use ACTON, Mass., March 12, 2026 -- Insulet Corporation (NASDAQ: PODD) (“Insulet” or th…
Read attachment ↗podd202512-31ex991.htm · 8-K · 2026-02-18
EX-99.1 2 podd202512-31ex991.htm EX-99.1 Document Exhibit 99.1 Insulet Reports Fourth Quarter and Full Year 2025 Results Fourth Quarter 2025 Revenue Increase of 31% (29% Constant Currency1) and Full Year 2025 Revenue Increase of 31% Year-Over-Year (30% Constant Currency) Represents 10th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass. - February 18, 2026 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pum…
Read attachment ↗